



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-IL-5 [SB-240563 (Mepolizumab)] Bulk Size Ab04155-3.0-BT

Isotype and Format: Mouse IgG2b, Kappa

Clone Number: SB-240563 (Mepolizumab)

Alternative Name(s) of Target: IL5; Interleukin-5; B-cell differentiation factor I; Eosinophil differentiation factor; T-cell replacing factor; TRF; h2B6; humanized 2B6

UniProt Accession Number of Target Protein: P05113

Published Application(s): therapeutic

Published Species Reactivity: Human

Immunogen: The original antibody was generated by grafting of CDRs from mouse parental antibody 2B6 onto human framework regions. The parental mouse antibody 2B6 was generated by immunizing mice with recombinant human IL-5.

Specificity: This antibody recognizes and binds human interleukin-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. This antibody does not cross react with mouse IL-5.

Application Notes: The pharmacokinetics of this antibody was investigated after intravenous and subcutaneous administration to cynomolgus monkeys. Suppression of eosinophil count was observed after multiple monthly administrations of this antibody to monkeys (PMID: 10565825). Pre-clinical efficacy and safety studies in cynomolgus monkeys demonstrated that chronic antagonism of IL-5 by mepolizumab is safe and has the potential to be beneficial therapy for chronic inflammatory respiratory diseases (PMID: 11496242). In a double-blind randomized placebo-controlled trial, the effects of treatment on responses to inhaled allergen challenge, sputum eosinophils, and airway hyper-responsiveness to histamine were measured at weeks 1 and 4 after a single intravenous infusion of this antibody. This antibody lowered the mean blood eosinophil count in placebo group and prevented the blood eosinophilia that follows allergen challenge. It also significantly reduced sputum eosinophilia seen after inhaled allergen challenge. It was further reported that this antibody had no significant effect to IL-5 on the late asthmatic response or on airway hyperresponsiveness to histamine (PMID: 11191542). In a double blind placebo-controlled study in asthmatic patients this antibody markedly reduced peripheral blood eosinophils without altering the distribution and activation status of lymphocytes (PMID: 12765424).

Antibody First Published in: Zia-Amirhosseini et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther. 1999 Dec;291(3):1060-7. [PMID:10565825](#)

Note on publication: This paper describes the pharmacokinetics and pharmacodynamics of a humanized

antibody SB-240563 against human IL-5.

Product Form

Size: 1 mg Purified antibody in bulk size.

Purification: Protein A affinity purified

Supplied In: PBS only.

Storage Recommendation: Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.